Detalhe da pesquisa
1.
A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
Prostate
; 84(4): 395-402, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38108113
2.
Local salvage of radiorecurrent prostate cancer.
Prostate
; 83(11): 1001-1010, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150849
3.
Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity.
Value Health
; 25(2): 171-177, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35094789
4.
Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer.
Acta Oncol
; 61(4): 468-477, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965846
5.
Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer.
Acta Oncol
; 59(10): 1164-1170, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32394776
6.
Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer.
Cancer Invest
; 37(2): 85-89, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30836776
7.
Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries.
Acta Oncol
; 58(7): 1036-1040, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30784340
8.
Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy.
Acta Oncol
; 58(3): 313-319, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30656994
9.
Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health.
Acta Oncol
; 57(5): 582-588, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29359988
10.
Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer.
Acta Oncol
; 56(7): 963-970, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28514929
11.
Sperm preservation and neutron contamination following proton therapy for prostate cancer study.
Acta Oncol
; 56(1): 17-20, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27420031
12.
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.
Cancer
; 120(7): 1076-82, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382757
13.
Proton therapy in stage II-IV non-small cell lung cancer: pattern of care and impact on trial accrual.
Acta Oncol
; 57(5): 692-693, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29103341
14.
Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.
Acta Oncol
; 52(3): 463-9, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23477359
15.
Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression.
Acta Oncol
; 52(3): 492-7, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23477360
16.
Outcomes in men with large prostates (≥ 60 cm(3)) treated with definitive proton therapy for prostate cancer.
Acta Oncol
; 52(3): 470-6, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23244673
17.
Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes.
Int J Part Ther
; 9(3): 18-29, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36721483
18.
Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger.
Cancer
; 118(18): 4619-26, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22253020
19.
Measuring Radiation Toxicity Using Circulating Cell-Free DNA in Prostate Cancer Patients.
Int J Part Ther
; 8(3): 28-35, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35127973
20.
Insurance Approval for Definitive Proton Therapy for Prostate Cancer.
Int J Part Ther
; 8(3): 36-42, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35127974